

Vesicare® (solifenacin) – First-time generic

- On April 22, 2019, <u>Teva launched</u> an <u>AB-rated</u> generic version of Astellas' <u>Vesicare (solifenacin)</u> tablets.
- Vesicare is approved for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- According to IQVIA data as of February 2019, Vesicare had annual sales of more than \$955 million in the U.S.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.